TY - JOUR
T1 - Dendritic cell-based immunotherapy
T2 - State of the art and beyond
AU - Bol, Kalijn F.
AU - Schreibelt, Gerty
AU - Gerritsen, Winald R.
AU - De Vries, I. Jolanda M.
AU - Figdor, Carl G.
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/4/15
Y1 - 2016/4/15
N2 - Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first explored in a clinical trial in the 1990s. More than two decades later, numerous clinical trials have been performed or are ongoing with a wide variety of DC subsets, culture protocols, and treatment regimens. The safety of DC vaccination and its ability to induce antitumor responses have clearly been established; however, although scattered patients with long-term benefit were reported, DC vaccines have not yet fulfilled their promise, perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible. To improve the efficacy of DC-based immunotherapy, it could be combined with other treatments.
AB - Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first explored in a clinical trial in the 1990s. More than two decades later, numerous clinical trials have been performed or are ongoing with a wide variety of DC subsets, culture protocols, and treatment regimens. The safety of DC vaccination and its ability to induce antitumor responses have clearly been established; however, although scattered patients with long-term benefit were reported, DC vaccines have not yet fulfilled their promise, perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible. To improve the efficacy of DC-based immunotherapy, it could be combined with other treatments.
UR - http://www.scopus.com/inward/record.url?scp=84966862666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966862666&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1399
DO - 10.1158/1078-0432.CCR-15-1399
M3 - Article
C2 - 27084743
AN - SCOPUS:84966862666
VL - 22
SP - 1897
EP - 1906
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 8
ER -